Fresenius Kabi has announced plans to purchase Merck KGaA’s biosimilars business.
Hands-on teaching offers drugmakers, vendors and regulators a better understanding of bioprocessing, according to the managing director of a training facility in Leiden, The Netherlands.
Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.
Danaher reported mid-single-digit growth from its bioprocessing subsidiary Pall Life Science and expects a continued trajectory to support Biopharma’s filtration needs.
The bioprocessing industry has donned its clogs and made its way to Amsterdam. And Biopharma-Reporter is here too, bringing you the best of BPI Europe 2017.
The US FDA has warned Lonza about operations at its facility in Walkersville, Maryland, raising concerns about validation and aseptic process simulations.